查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011293

血糖值監測設備市場：2026-2032年全球市場預測（依設備類型、技術、應用、最終用戶及通路分類）

Glucose Monitoring Devices Market by Device Type, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血糖值監測設備市場價值將達到 93.4 億美元，到 2026 年將成長至 103.6 億美元，到 2032 年將達到 217.4 億美元，複合年成長率為 12.81%。

主要市場統計數據
基準年 2025 93.4億美元
預計年份：2026年 103.6億美元
預測年份 2032 217.4億美元
複合年成長率 (%) 12.81%

整體情況不斷發展的血糖監測技術，包括技術進步、臨床應用趨勢和相關人員的優先事項。

血糖監測領域正經歷快速的技術和商業性變革，徹底改變了臨床醫生、看護者和糖尿病患者管理血糖的方式。感測器小型化、數據連接和演算法分析的進步，以及不斷發展的診療路徑，正在為慢性病管理建立新的模式。本文概述了關鍵促進因素和框架假設，為深入分析市場動態、市場區隔、區域差異和策略意義奠定了基礎。

對技術、監管和商業性變革的整合進行詳細分析，這些變革正在重新定義血糖監測的產品價值和護理路徑。

血糖監測領域正經歷一系列相互關聯的變革，這些變革正在重新定義產品價值、醫療服務模式和競爭優勢。感測器精度的提升，以及可長期佩戴和微創外形規格的出現，正將應用場景從傳統的糖尿病管理擴展到預防性監測和手術全期護理。同時，可互通的數據生態系統和雲端原生分析技術正在催生以遠端監測、人群健康管理和決策支援為核心的新服務，從而改變了設備製造商和軟體合作夥伴的預期。

對 2025 年關稅變化將如何重塑整個血糖監測價值鏈的供應鏈、採購決策和商業策略進行策略評估。

2025年新關稅措施的實施對整個血糖監測生態系統的供應鏈、籌資策略和定價產生了連鎖反應。依賴國際採購零件的製造商面臨著不斷上漲的進口成本，迫使許多公司重新評估其採購地點並實現供應商多元化。對於在受影響地區以外擁有垂直整合製造地的公司而言，關稅環境獎勵其加快本地化進程並發展區域供應商，以確保生產的連續性並最佳化單位經濟效益。

詳細的細分分析揭示了設備類型、技術選擇、臨床應用、最終用戶環境和分銷管道如何決定差異化的創新和市場進入方式。

細分市場分析揭示了從設備類型、技術、應用、最終用戶和分銷管道等方面來看，創新軌跡和擴散模式存在差異。按設備類型分類，連續血糖監測 (CGM) 和瞬時血糖監測 (FGM) 與自我血糖監測 (SMBG) 形成鮮明對比。此外，CGM 本身又可細分為「個人」和「商用」兩種，以滿足不同的臨床工作流程和支付方要求。技術差異進一步加劇了市場格局的細分。包括比色法和電化學安培法在內的侵入性方法與皮下感測器等微創方法以及利用光學光譜和經皮取的非侵入性方法並存，每種途徑都面臨著各自的監管挑戰和用戶體驗方面的權衡取捨。

概述區域趨勢，解釋地理管理體制、支付方結構和醫療保健服務模式如何為血糖監測的實施創造不同的路徑。

區域趨勢對監管路徑、報銷模式和普及率產生了重大影響，在美洲、歐洲、中東、非洲和亞太地區帶來了不同的戰略挑戰。在美洲，臨床醫生主導的推廣應用和早期與支付方的合作推動了先進監測解決方案的快速普及，這些解決方案強調與電子健康記錄和遠端監測平台的互通性。這種環境有利於那些能夠展示臨床療效、無縫整合到臨床醫生工作流程中並有效利用複雜報銷框架的供應商。

對競爭格局進行評估，以確定決定血糖監測生態系統領導地位的策略性舉措、夥伴關係模式和能力差距。

血糖監測領域的競爭格局呈現出多元化的特點，既有成熟的醫療設備製造商，也有專注於糖尿病技術的公司，還有一些來自其他行業、提供軟體和數據能力的參與企業。主要企業正大力投資於感測器效能、使用者體驗和臨床證據，以保持其差異化優勢；而敏捷的新興企業則專注於創新的外形規格、定價模式和軟體驅動型服務。整個競爭格局中出現的策略性舉措包括：感測器和分析能力的垂直整合、拓展與保險公司和醫療保健系統的夥伴關係，以及透過有針對性的收購來加速互補技術的市場推廣。

為製造商和相關人員提供切實可行的優先建議，以協調臨床檢驗、商業化模式和業務永續營運，從而確保永續的競爭優勢。

產業領導者應優先考慮一系列切實可行的舉措，使產品開發、證據產生和商業性執行與不斷變化的臨床和支付方預期保持一致。首先，投資於能夠將醫療設備效能轉化為對病患和醫療保健系統有意義的結果的臨床研究至關重要，這有助於推動醫保報銷談判和產品差異化。為了補充臨床證據，企業應開發模組化的商業模式，將醫療設備、資訊服務和教育支援結合，以提高客戶留存率並實現收入來源多元化。

對用於評估醫療設備技術、臨床應用和商業性趨勢的調查設計、資料來源和分析方法進行透明的解釋。

本研究整合了初級調查和二級調查的方法，並對目前血糖監測現狀進行了嚴謹且可重複的評估。初級調查包括對臨床醫生、採購經理和技術主管的結構化訪談，並輔以技術檢驗和臨床環境中的觀察性評估，以支持關於可用性和整合挑戰的論點。二級調查則利用同儕審查的臨床文獻、監管文件和公開資料，建構了關於技術性能和監管趨勢的可靠證據基礎。

策略整合強調整合技術、證據和商業策略如何決定哪些組織能夠將創新轉化為持久的臨床和商業性影響。

總之，我們整合了本報告的關鍵主題，並重點闡述了其對相關人員在不斷變化的血糖監測領域中的策略意義。技術創新正在催生更豐富、更連續的資料集，從而支持更積極主動的慢性病管理，但要充分發揮這一潛力，需要臨床檢驗、監管策略和支付方合作的協調一致。成功整合卓越硬體、擴充性數據分析和以用戶為中心的設計的市場參與企業，將在所有醫療保健機構中獲得更廣泛的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章血糖值監測設備市場：依設備類型分類

  • 持續血糖監測
    • 個人
    • 專業的
  • 瞬時血糖監測
  • 自我血糖測量

第9章：血糖值監測設備市場：依技術分類

  • 侵襲型
    • 比色法
    • 電化學安培法
  • 微創
  • 非侵入性
    • 光學光譜學
    • 經皮取

第10章：血糖值監測設備市場：依應用領域分類

  • 妊娠糖尿病
  • 1型糖尿病
  • 2型糖尿病

第11章血糖值監測設備市場：依最終用戶分類

  • 門診治療
  • 居家照護
  • 醫院
    • 私立醫院
    • 公立醫院

第12章血糖值監測設備市場：依通路分類

  • 網路商店
    • 企業網站
    • EC平台
  • 離線

第13章血糖值監測設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章血糖值監測設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章血糖值監測設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血糖值監測設備市場

第17章：中國血糖值監測設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AgaMatrix, Inc.
  • ARKRAY, Inc.
  • Ascensia Diabetes Care
  • Bigfoot Biomedical, Inc.
  • Dexcom, Inc.
  • EKF Diagnostics Holdings plc
  • ForaCare Inc.
  • GlucoRx Ltd
  • i-SENS, Inc.
  • Insulet Corporation
  • LifeScan, Inc.
  • Medtronic plc
  • Menarini Diagnostics
  • Nova Biomedical Corporation
  • Roche Diagnostics
  • Senseonics Holdings, Inc.
  • Sinocare Inc.
  • Tandem Diabetes Care, Inc.
  • Ypsomed AG
Product Code: MRR-436B79517C57

The Glucose Monitoring Devices Market was valued at USD 9.34 billion in 2025 and is projected to grow to USD 10.36 billion in 2026, with a CAGR of 12.81%, reaching USD 21.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.34 billion
Estimated Year [2026] USD 10.36 billion
Forecast Year [2032] USD 21.74 billion
CAGR (%) 12.81%

A comprehensive orientation to the evolving glucose monitoring landscape that frames technological advances, clinical adoption patterns, and stakeholder priorities

The landscape of glucose monitoring is undergoing rapid technological and commercial change, reshaping how clinicians, caregivers, and people with diabetes monitor glycemic control. Advances in sensor miniaturization, data connectivity, and algorithmic analytics are converging with shifting care pathways to create new models for chronic disease management. This introduction synthesizes core drivers and framing assumptions to set the stage for deeper analysis across market dynamics, segmentation, regional variation, and strategic implications.

In recent years, the focus has moved from episodic fingerstick testing toward continuous and real-time monitoring paradigms that emphasize longitudinal data and actionable insights. This transition has implications for device design, regulatory strategy, reimbursement engagement, and end-user experience. The result is a competitive environment where incumbent medical device manufacturers, specialized diabetes technology firms, and emerging digital health players are adjusting their propositions to emphasize connectivity, ease of use, and clinical integration. As stakeholders deliberate product development, clinical evidence generation, and commercialization pathways, a clear understanding of technological trends and regulatory pressures will be essential to navigate near-term disruptions and unlock sustained adoption.

An in-depth look at the converging technological, regulatory, and commercial shifts that are redefining product value and care pathways in glucose monitoring

The glucose monitoring sector is being transformed by a set of interrelated shifts that are redefining product value, care delivery, and competitive advantage. Sensor accuracy improvements combined with extended-wear and minimally invasive form factors are expanding use cases beyond conventional diabetes management into preventive monitoring and perioperative care. At the same time, interoperable data ecosystems and cloud-native analytics are enabling new services around remote monitoring, population health management, and decision support, which in turn alter expectations for device manufacturers and software partners.

Regulatory pathways are evolving to accommodate software as a medical device and adaptive algorithms, increasing emphasis on real-world evidence and post-market surveillance. Payer approaches are also changing, with value-based agreements and outcomes-based reimbursement models gaining traction in selective markets. These systemic shifts pressure firms to align clinical evidence strategies with commercial models and to invest in cross-disciplinary capabilities spanning hardware, software, and services. Consequently, leaders who integrate user-centered design, robust clinical validation, and scalable data infrastructures will capture outsized strategic options as the market matures.

A strategic appraisal of how tariff changes in 2025 reshaped supply chains, sourcing decisions, and commercial strategies across the glucose monitoring value chain

The imposition of new tariff measures in 2025 created a series of cascading effects on supply chains, sourcing strategies, and pricing decisions across the glucose monitoring ecosystem. Manufacturers relying on internationally sourced components faced increased landed costs, prompting many to re-evaluate sourcing footprints and supplier diversification. For companies with vertically integrated manufacturing outside affected jurisdictions, the tariff environment incentivized accelerated localization or regional supplier development to insulate production continuity and to manage unit economics.

Beyond direct cost pressures, tariffs influenced strategic choices around product configuration and procurement timing. Several firms prioritized higher-margin, subscription-based services and bundled offerings to protect revenue streams from one-time device price compression. Health systems and large purchasers reacted by updating procurement frameworks to incorporate total cost of ownership considerations rather than headline unit cost alone. Meanwhile, regulatory filings and supply chain certifications took on new importance as manufacturers sought to document origin and compliance, increasing programmatic costs for market entry. The cumulative effect has been a rebalancing of commercial playbooks toward resilience, supplier redundancy, and closer alignment between product roadmaps and procurement risk tolerance.

A granular segmentation synthesis revealing how device type, technology choices, clinical application, end-user settings, and distribution channels dictate differentiated innovation and go-to-market approaches

Segmentation analysis reveals differentiated innovation trajectories and adoption contours when examined across device type, technology, application, end user, and distribution channel. When framed by device type, Continuous Glucose Monitoring and Flash Glucose Monitoring contrast with Self Monitoring of Blood Glucose, while Continuous Glucose Monitoring itself bifurcates into Personal and Professional variants that address distinct clinical workflows and payer requirements. Technology distinctions further refine the landscape: Invasive approaches, including Colorimetric and Electrochemical Amperometric techniques, continue to coexist with Minimally Invasive options typified by subcutaneous sensors and Non Invasive modalities that leverage optical spectroscopy or transdermal extraction, each path presenting unique regulatory and user-experience trade-offs.

Application-based segmentation highlights that device design and service models are being tailored to the needs of gestational diabetes care, Type 1 diabetes management, and the larger population living with Type 2 diabetes, with clinical evidence and educational support varying accordingly. End-user segmentation splits demand across ambulatory care settings, home care environments, and hospital settings, where hospitals further divide into private and public institutions with different procurement constraints and clinical protocols. Finally, distribution channel distinctions shape commercialization strategies, with hospital pharmacies, online stores-encompassing company websites and e-commerce platforms-and retail pharmacies, made up of chain and independent outlets, enabling diverse go-to-market approaches. Taken together, these segmentation lenses demonstrate that product design, evidence generation, and commercial execution must be tightly aligned to the needs and constraints of targeted customer cohorts.

A regional intelligence overview explaining how geographic regulatory regimes, payer structures, and healthcare delivery models create distinct pathways for glucose monitoring adoption

Regional dynamics exert a material influence on regulatory pathways, reimbursement models, and adoption rates, producing distinct strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinician-led adoption and early payer engagement have supported rapid uptake of advanced monitoring solutions, with an emphasis on interoperability with electronic health records and remote monitoring platforms. This environment has favored vendors who can demonstrate clinical outcomes and integrate seamlessly into clinician workflows while navigating complex reimbursement frameworks.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory standards, public procurement practices, and health system fragmentation require agile market-entry plans that account for national differences in approval timelines and payer expectations. Partnerships with local distributors and clinicians are often critical to build trust and to adapt evidence packages to local standards. The Asia-Pacific region features a broad spectrum of market maturity, with highly competitive urban centers advancing telehealth-enabled solutions and more price-sensitive markets emphasizing cost-effective devices and scalable distribution models. Across all regions, regulatory harmonization efforts and cross-border data governance debates will continue to shape commercialization strategies and product design priorities.

A competitive landscape assessment that identifies strategic moves, partnership patterns, and capability gaps that determine leadership in the glucose monitoring ecosystem

Competitive dynamics in glucose monitoring are characterized by a mix of established medical device manufacturers, specialized diabetes technology companies, and cross-sector entrants that bring software and data capabilities. Leading players have invested heavily in sensor performance, user experience, and clinical evidence to defend differentiated positions, while agile challengers focus on disruptive form factors, pricing models, and software-enabled services. Strategic initiatives observed across the competitive set include vertical integration of sensor and analytics capabilities, expansion of partnerships with payers and health systems, and targeted acquisitions to accelerate time to market for complementary technologies.

Companies that succeed are those that balance robust clinical validation with scalable manufacturing and a clear commercialization pathway that addresses the needs of providers, payers, and patients. Collaboration between hardware teams and algorithm developers has become a prerequisite for delivering meaningful insights rather than raw data. In addition, effective engagement with distribution partners and digital health platforms enhances reach and adherence, particularly in home care settings. As the industry evolves, the ability to orchestrate cross-functional capabilities and demonstrate real-world impact will determine which companies capture leadership positions.

Practical and prioritized recommendations for manufacturers and stakeholders to align clinical validation, commercialization models, and operational resilience for sustained advantage

Industry leaders should prioritize a set of pragmatic actions that align product development, evidence generation, and commercial execution to evolving clinical and payer expectations. First, investment in clinical studies that link device performance to meaningful patient and health system outcomes will be essential to support reimbursement dialogues and to differentiate offerings. Complementing clinical evidence, firms should develop modular commercial models that combine devices, data services, and educational support to increase stickiness and diversify revenue streams.

Operationally, companies must strengthen supply chain resilience through supplier diversification, manufacturing flexibility, and clear traceability of component origins. Strategic partnerships with digital health platforms and electronic health record providers will accelerate integration into clinical workflows and enhance perceived value among providers. Finally, organizations should build capability in post-market data analytics and regulatory compliance for adaptive software, enabling iterative improvement and sustained regulatory alignment. These combined actions will position firms to capture demand while managing cost and regulatory pressures across diverse markets.

A transparent explanation of research design, data sources, and analytical methods used to evaluate device technologies, clinical adoption, and commercial dynamics

This study synthesizes primary and secondary research approaches to provide a rigorous, reproducible assessment of the glucose monitoring landscape. Primary research included structured interviews with clinicians, procurement leaders, and technology executives, supplemented by technical validations and observational assessments in clinical environments to ground claims about usability and integration challenges. Secondary research drew on peer-reviewed clinical literature, regulatory documents, and public filings to construct a robust evidence base for technology performance and regulatory trends.

Analytical methods combined qualitative coding of interview data with thematic synthesis to identify recurring strategic priorities, while technology assessments evaluated sensor modalities against clinical criteria such as accuracy, wearability, and data interoperability. Care was taken to validate claims through triangulation across multiple sources and to flag areas where evidence remains emergent. Limitations of the approach are acknowledged, including variability in clinical practice across regions and the rapid pace of innovation that can shift competitive dynamics between research cycles. Where appropriate, recommendations reflect the degree of evidentiary confidence and highlight opportunities for targeted primary research to reduce uncertainty.

A strategic synthesis highlighting how integrated technology, evidence, and commercial strategies will determine which organizations convert innovation into durable clinical and commercial impact

The conclusion synthesizes the report's central themes and underscores the strategic implications for stakeholders seeking to navigate the evolving glucose monitoring environment. Technological innovation is enabling richer, continuous datasets that support more proactive chronic disease management, but realizing this promise requires alignment among clinical validation, regulatory strategy, and payer engagement. Market participants that successfully integrate hardware excellence with scalable data analytics and user-centered design will unlock broader adoption across care settings.

Operational resilience and adaptive commercialization models are equally important given geopolitical and trade disruptions that influence cost and supply continuity. Regional nuances will persist, demanding localized evidence and tailored engagement with clinicians and procurement entities. Ultimately, the competitive battleground will be defined by the ability to demonstrate measurable clinical and economic value while delivering an intuitive, low-friction experience for end users. Organizations that act decisively on these priorities will be best positioned to translate innovation into meaningful patient and system-level outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glucose Monitoring Devices Market, by Device Type

  • 8.1. Continuous Glucose Monitoring
    • 8.1.1. Personal
    • 8.1.2. Professional
  • 8.2. Flash Glucose Monitoring
  • 8.3. Self Monitoring Of Blood Glucose

9. Glucose Monitoring Devices Market, by Technology

  • 9.1. Invasive
    • 9.1.1. Colorimetric
    • 9.1.2. Electrochemical Amperometric
  • 9.2. Minimally Invasive
  • 9.3. Non Invasive
    • 9.3.1. Optical Spectroscopy
    • 9.3.2. Transdermal Extraction

10. Glucose Monitoring Devices Market, by Application

  • 10.1. Gestational Diabetes
  • 10.2. Type 1 Diabetes
  • 10.3. Type 2 Diabetes

11. Glucose Monitoring Devices Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Glucose Monitoring Devices Market, by Distribution Channel

  • 12.1. Online Stores
    • 12.1.1. Company Websites
    • 12.1.2. E Commerce Platforms
  • 12.2. Offline

13. Glucose Monitoring Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glucose Monitoring Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glucose Monitoring Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Glucose Monitoring Devices Market

17. China Glucose Monitoring Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AgaMatrix, Inc.
  • 18.7. ARKRAY, Inc.
  • 18.8. Ascensia Diabetes Care
  • 18.9. Bigfoot Biomedical, Inc.
  • 18.10. Dexcom, Inc.
  • 18.11. EKF Diagnostics Holdings plc
  • 18.12. ForaCare Inc.
  • 18.13. GlucoRx Ltd
  • 18.14. i-SENS, Inc.
  • 18.15. Insulet Corporation
  • 18.16. LifeScan, Inc.
  • 18.17. Medtronic plc
  • 18.18. Menarini Diagnostics
  • 18.19. Nova Biomedical Corporation
  • 18.20. Roche Diagnostics
  • 18.21. Senseonics Holdings, Inc.
  • 18.22. Sinocare Inc.
  • 18.23. Tandem Diabetes Care, Inc.
  • 18.24. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PERSONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PROFESSIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY SELF MONITORING OF BLOOD GLUCOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ELECTROCHEMICAL AMPEROMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OPTICAL SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TRANSDERMAL EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GCC GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 218. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 221. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. G7 GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 229. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 232. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL GLUCOSE MONITORING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY NON INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA GLUCOSE MONITORING DEVICES MARKET SIZE, BY ONLINE STORES, 2018-2032 (USD MILLION)